To systematically evaluate the immunomodulatory effects of TCM in NSCLC, we selected T cell subsets (CD3+, CD4+, CD8+, CD4+/CD8+ ratio) as key endpoints. Here, CD8A is linked to non-small cell lung carcinoma.